TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05734417

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Oral administration of Bifidobacterium lactis subsp. infantis B8762 at 0.5x10 log colony forming unit (CFU)/day for 4-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intervention consists of daily administration of 2g/sachet of excipient administered daily for 4-weeks
Study: NCT05278598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: After skin sterilization, ESP block will be performed at the level of T9. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T9 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 30 mL of 0.25% bupivacaine will be injected. Sonographic confirmation of the local anesthetic spread will be seen as an anechoic shadow in the paravertebral spaces from T7 to T12.~This procedure will be done on both sides.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Plane Block
Description: After skin sterilization, curvilinear high-frequency ultrasound transducer will be used to visualize the T10 paravertebral space in the paramedian sagittal plane. An injection into the paravertebral space will spread to multiple adjacent dermatomes, so exact identification of a specific level will be not necessary. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe and slowly be directed from lateral to medial until its tip was located at the apex of the paravertebral space and the endpoint for successful block will be anterior displacement of the pleura by injected local anesthetic where a single injection of 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides.
Study: NCT06249750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.
Study: NCT05278598

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Plane Block
Description: After skin sterilization, curvilinear high-frequency ultrasound transducer will be positioned horizontally in the anterior axillary line halfway between the subcostal margin and iliac crest, to locate the triple abdominal muscle layers, then the probe will be relocated subsequently to the posterior axillary line until the quadratus lumborum muscle could be visualized with its attachment to the lateral edge of the transverse process of the L4 vertebral body. With the psoas major muscle anteriorly, the erector spinae muscle posteriorly and the quadratus lumborum muscle adherent to the apex of the transverse process, this is a well-recognizable pattern of a shamrock with three leaves. A 22-gauge spinal needle will be inserted in-plane relative to the ultrasound probe passing in posterior to anterior direction through the quadratus lumborum to reach the border between it and psoas major, where 30 ml of 0.25% bupivacaine will be injected.~This procedure will be done on both sides.
Study: NCT05766358

Intervention type: BEHAVIORAL
Intervention: Intensive lifestyle change therapy
Description: Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up

Intervention type: DRUG
Intervention: Tirzepatide
Description: Participant of both groups will be followed for 24 months after completing the parent trial intervention, with no intervention during the follow-up
Study: NCT06249750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy is currently a hot spot in the field of tumor research. Immune Checkpoint Inhibitor (ICI) is a monoclonal antibody designed to target the negative immunoregulatory pathway overexpressed in tumor cells, which can release the anti-tumor immunosuppressive signals and restore the killing of tumors by the immune cells, and thus exert anti-tumor effects. ICI regimen: Tislelizumab, 200mg, ivgtt., d1, q21d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Description: Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Targeted therapy
Description: Recent studies have found that the combination of RTK inhibitors and ICIs can exert synergistic effects on different mechanisms, which can compensate for the deficiencies of single-agent RTK inhibitors and single-agent ICIs in the treatment of CRPC and become a potential novel therapeutic strategy for solid malignant tumors. RTK inhibitor regimen: Anlotinib, 12mg, po., d2\~15, q21d.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Thermal stimulation is a rapidly developing physiotherapeutic tool, which is playing an increasingly important role in the field of comprehensive tumor therapy due to its unique low adverse effects and high compatibility. A large number of clinical studies have shown that the addition of heat stress to multimodal tumor therapy does not significantly increase toxicity and side effects, and the combination of heat stress with other therapies can have the effect of 1+1\>2. ET-SPACE near-infrared irradiation whole-body hyperthermia: d1, d8, q21d, rectal temperature reaches 38.5\~39 ℃ and then maintain 1h.
Study: NCT04529291

Intervention type: OTHER
Group type: OTHER
Intervention: Group with walking disorder
Description: During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital. Additional home visits, corresponding to intervention, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
Study: NCT05286203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metagenomic Deep Sequencing (MDS)
Description: MDS is an RNA-seq based testing of ocular fluid or tissue to identify potential infectious pathogens including bacteria, fungi, parasites, and DNA and RNA viruses.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: SOC includes any available diagnostic tests, such as Gram stain, cultures, PCRs, that are considered the appropriate testing based on the clinical findings.
Study: NCT06321991

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E-creme (Remederm®) vs Vaseline (Placebo)
Description: Louis Widmer Remederm® Face Cream Without Perfume 50 ml is a skin care product that contains vitamin E as an active ingredient. Before applying Remederm®, the following are advised: On dry clean skin thoroughly before applying Remederm®, apply a layer of cream cutaneous to the hand palm, twice a day: morning and evening, massage cream into skin until absorbed. This procedure is applied by the patient treated with Vaseline or Remederm®.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin E-creme (Remederm®) vs Vaseline (Placebo)
Description: Louis Widmer Remederm® Face Cream Without Perfume 50 ml is a skin care product that contains vitamin E as an active ingredient. Before applying Remederm®, the following are advised: On dry clean skin thoroughly before applying Remederm®, apply a layer of cream cutaneous to the hand palm, twice a day: morning and evening, massage cream into skin until absorbed. This procedure is applied by the patient treated with Vaseline or Remederm®.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound measurement
Description: Nodule evolution will be measured with ultrasound.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ultrasound measurement
Description: Nodule evolution will be measured with ultrasound.
Study: NCT05226923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP-1007
Description: Single and multiple doses, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP-1007
Description: Single and multiple doses, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KSP-1007
Description: Single and multiple doses, intravenous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:0.9% sodium chloride
Description: Single and multiple doses, intravenous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:0.9% sodium chloride
Description: Single and multiple doses, intravenous administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo:0.9% sodium chloride
Description: Single and multiple doses, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropenem
Description: Multiple doses, intravenous administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Meropenem
Description: Multiple doses, intravenous administration
Study: NCT06324838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard laparoscopic ileocecal resection
Description: Participants will undergo standard mesocolic sparing resection.
Study: NCT05977881

Intervention type: OTHER
Group type: OTHER
Intervention: CHECKIT!
Description: Participants will not be assigned to the intervention as it will be available to everyone.~Check it will be a van-based HIV- and overdose-prevention program offered in the four areas of Baltimore city from which study participants are recruited. Intervention services will include point-of-care drug checking and PrEP assessment, prescription, and management, and they will be available to everyone, regardless of whether they are part of the SCOPE study cohort or not.~Individual-level service usage data collected by intervention staff will not be considered in analysis of outcomes. However, study participants will self-report Check it utilization on the internally-developed surveys at 6, 12, and 18 months.
Study: NCT05202964

Intervention type: OTHER
Intervention: Tolerance and adherence to oral antibiotics in patients managed for BJI
Description: Adherence and tolerance will be measured 6 weeks (S6) and 3 months (M3) after the surgery.~The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire) Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.~Patients will respond to a questionnaire about the tolerance on the consultation at S6 and M3.
Study: NCT04475198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-2427
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-2427
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-2427
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-2427
Description: Investigational drug
Study: NCT06324838

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended laparoscopic ileocecal resection
Description: Extended mesocolic resection to assess its impact on reducing recurrence at the anastomotic site.
Study: NCT04475198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-2427
Description: Investigational drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 5% Dextrose Injection
Study: NCT04529291

Intervention type: OTHER
Group type: OTHER
Intervention: Group without walking disorder
Description: During the patient's hospitalization, two questionnaires will be completed, assessing the handicap of the patient in his daily activities, and the specific incapacity to carry out activities of daily living and social life (10 minutes to complete). The patient will then carry out two 20-meter round-trip walking tests during his first day and his last day of care at the hospital.~Additional home visits, corresponding to interventions, performed by a member of the investigative team, will take place once a week (15-20 minutes). The team will collect his feelings about the evolution of symptoms through the two questionnaires, and quantify the evolution of his walking. Walk tests are recorded using small inertial sensors (accelerometers and gyrometers) that will be placed at his feet, belt and forehead. This examination is not painful. All the measurements are carried out in 15 minutes by a member of the team.
Study: NCT05873881

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine 0.5 MG
Description: Oral colchicine 0.5 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchicine placebo
Description: Placebo colchicine daily
Study: NCT04985344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Oral Product
Description: Child will receive oral propranolol (syrup). The dose of propranolol will increase gradually over the first 3 treatment sessions in order to assess tolerance.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Child will receive oral placebo (syrup). The dose of placebo will increase gradually over the first 3 treatment sessions in order to match propranolol intervention.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: memory reactivation
Description: 90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: memory reactivation
Description: 90 minutes after the propranolol take, a trained psychologist will ask the child to recount his trauma.
Study: NCT06340217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: washed microbiota transplantation
Description: Washed microbiota transplantation refers to the infusion of washed microbiota from healthy donor into patients' gastrointestinal tract. Participants will receive two doses of WMT for DGP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: A carrier fluid with matching volume and consistent appearance to the infusion of washed microbiota.
Study: NCT04810780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DUO Extended Set
Description: to evaluate saftey and efficacy of DUO extended set combined with glucose sensor
Study: NCT05315011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy
Description: The term cryotherapy refers to the process of chilling the body for medicinal purposes. WBC is carried out in a dedicated temperature and humidity controlled cryogenic chamber, which includes a brief exposure to extremely cold air. To avoid frostbite, only a few layers of clothes will be worn during the exposure. To avoid skin burns and necrosis, each participant must first remove their sweat before entering the cryochamber and a surgical mask is also worn to prevent moist air from being exhaled. Subjects will move their fingers and legs in the cryochamber and avoid holding their breath. The exposure time will be 4 minutes and 30 seconds in -85°C.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cryotherapy
Description: The patient will be placed in a -85°C chamber for 1 minute as part of the placebo treatment.
Study: NCT04152993

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroPace® RNS® System
Description: In this intervention, patients suffering from PTSD undergo a surgical procedure to implant the responsive neurostimulation device (RNS, NeuroPace). This procedure involves the placement of a depth lead bilaterally in the amygdala and hippocampus following a trans-occipital trajectory. The two leads are then connected to a pulse generator fixated to the skull. RNS is able to detect specific signals from the target and to respond with a programmed electrical stimulation. One month after the implantation of the system, the patients will undergo 3 tasks: a fear conditioning task, the international affective picture system and the subsequent memory recall paradigm. These tasks will yield electrophysiological biomarkers of arousal and re-experiencing. We will then program RNS to detect and respond to those biomarkers. The patients will be followed longitudinally for improvement and evidence of target engagement as seen on cerebral metabolism and global electroencephalography.
Study: NCT05408793

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Pulse Stimulation
Description: A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Pulse Stimulation
Description: A total of 36 participants (both TPS group and the sham-control group) will receive six 30 minute-TPS sessions (800 pulse in each session, total: 4800 pulse) in 2 weeks' time (i.e., 3 sessions (Monday, Wednesday, Friday) per week, total: 3 hours), on a 1: 1 allocation ratio. Participants will be followed up immediately after the post-stimulation and at 1-month and 3-month period after the intervention. A 2-week TPS intervention alongside with 3-month follow-up is sufficient enough to test the effects of TPS on autism symptoms.
Study: NCT05873881

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine Mononitrate 300 mg
Description: Thiamine Mononitrate 300 mg daily
Study: NCT05389852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: After completion of supraclavicular brachial plexus block patients will receive intravenous dexmedetomidine 1 mcg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: After completion of supraclavicular brachial plexus block patients will receive intravenous dexmedetomidine 1 mcg/kg
Study: NCT04882969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fractionated Thulium laser
Description: LaseMD Lutronic Laser is a 1927-nm fractionated thulium laser, which is better absorbed by water than non-ablative 1,540-nm erbium glass laser energy. The laser energy and power can be customized to target a specific penetration depth and achieve selective photothermolysis in skin while mitigating injury to surrounding tissue. The thermal energy generated by the laser has been shown to facilitate the delivery of kerafactor, which contain hair growth factors to stimulate follicular progenitor cell proliferation and differentiation into follicular keratinocytes to promote hair growth.
Study: NCT06213428

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Perfect Probiotic
Description: Participants will be administered an active probiotic for 28 days. Participants will be blinded as to what intervention they are experiencing.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered a placebo for 28 days. Participants will be blinded as to what intervention they are experiencing.
Study: NCT05562401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coconut Water
Description: Coconut water is the clear fluid inside the coconut, has natural electrolytes such as potassium, sodium and manganese.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sport Drink
Description: A type to sport drink is isotonic drink. Is an industrialized drink that containing water, carbohydrates, and 4-8% electrolytes.
Study: NCT04838808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 2.5 MG [Xarelto]
Description: Rivaroxaban 2.5mg twice daily for 90-days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet twice daily for 90-days
Study: NCT06065098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD
Description: The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension, diabetes, and hypercholesterolemia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Evidence-based interventions recommended by the 2019 ACC/AHA Guideline on the Primary Prevention of CVD
Description: The recommended evidence-based interventions include therapeutic lifestyle change and medical treatment of hypertension, diabetes, and hypercholesterolemia.
Study: NCT05328947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Functional Reach and Functional Reach
Description: Establishment of Modified Functional Reach Test (mFRT) and Function Reach Test (FRT) values for individuals with no functional impairments.